Loading clinical trials...

COMPLETEDPhase 1NCT00509301

Safety & Radiation Distribution Study of Cotara® in Patients With Recurrent Glioblastoma Multiforme

RATIONALE: Cotara® is an experimental new treatment that links a radioactive isotope (iodine 131) to a targeted monoclonal antibody. This monoclonal antibody is designed to bind tumor cells and delive...

Lead sponsor: Peregrine Pharmaceuticals•4 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Related studies

RECRUITINGPhase 1/2

A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of JL15003 Injection in Patients With Recurrent Glioblastoma (rGBM)

NCT07501559 · Recurrent Glioblastoma Multiforme(GBM)

Enrolling By InvitationPhase 1

The Safety and Efficacy of SNC-109 CAR-T Cells Therapy the rGBM

NCT06616727 · Recurrent Glioblastoma Multiforme (GBM)

COMPLETEDPhase 2

Bi-weekly Temozolomide Plus Bevacizumab for Adult Patients With Recurrent Glioblastoma Multiforme

NCT00883298 · Recurrent Glioblastoma Multiforme, Recurrent Gliosarcoma

UNKNOWNPhase 2

Procarbazine and Lomustine in Recurrent Glioblastoma

NCT01737346 · Recurrent Glioblastoma Multiforme

COMPLETEDPhase 2

Safety and Efficacy Study to Treat Recurrent Grade 4 Malignant Brain Tumors

NCT00071539 · Recurrent Glioblastoma Multiforme

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: August 5, 2011Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE1

Enrollment12

Start dateNov 2006

Last updatedAug 5, 2011

Condition

Recurrent Glioblastoma Multiforme

Locations shown

Barrow Neurological Institute

Phoenix, Arizona

University Hospitals Case Medical Center

Cleveland, Ohio

University of Pennsylvania

Philadelphia, Pennsylvania

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 5, 2011Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions